LONHALA® MAGNAIR® (glycopyrrolate) COPD Device Satisfaction Data

Rates of Device Satisfaction With LONHALA MAGNAIR

Device satisfaction in a post hoc analysis of GOLDEN-51

GOLDEN-5 was a 48-week, randomized, open-label, parallel-group, multicenter trial to assess the safety and efficacy of LONHALA MAGNAIR 50 mcg twice daily vs tiotropium 18 mcg once daily in patients with moderate to very severe COPD.

Of the 620 patients in the LONHALA MAGNAIR group, 454 completed a Sunovion-generated 20-item questionnaire at Week 48 about their experience with MAGNAIR (note that the 50-mcg dosage strength is not approved for use; the approved 25-mcg dosage strength was not evalueated in this trial).

The questionnaire evaluated patients' perceptions of MAGNAIR ease of use, confidence in drug delivery, overall satisfaction, and willingness to use the device. Patients were also questioned about devices they used prior to study enrollment and how MAGNAIR compared with other nebulizers they may have used in the past. In GOLDEN-5, 82% of patients had prior experience with a metered-dose inhaler or dry-powder inhaler, and 38% had previous experience with a nebulizer.

Validation of this questionnaire was not conducted, and comparisons could not be drawn about device use and satisfaction with the active control group. Approximately 27% of patients did not complete the questionnaire at the end of the study, making their experience with the device unknown. Patient responses to questions about prior nebulization use may include recall bias. It should also be noted that patients with compromised dexterity or cognition may require assistance setting up and cleaning a nebulized device.

In a post hoc analysis of an open-label, long-term safety study, patients reported the following about their experience using LONHALA MAGNAIR1:

Size

89% said the device was the "ideal" size*

*Handset is 2.4 x 4.7 inches. Controller is 1.6 x 4.6 inches.2

Size

89% said the device was the "ideal" size*

*Handset is 2.4 x 4.7 inches. Controller is 1.6 x 4.6 inches.2


Ease of use

>70% found assembly, operation, and cleaning "easy" or "very easy"

Ease of use

>70% found assembly, operation, and cleaning "easy" or "very easy"


Confidence in administration

83% reported being "confident" or "very confident" in the administration of the medication

Confidence in administration

83% reported being "confident" or "very confident" in the administration of the medication


Device Weight

88% rated the device as light

MAGNAIR weighs 10.2 ounces (including batteries).1

Device Weight

88% rated the device as light

MAGNAIR weighs 10.2 ounces (including batteries).1


Overall Satisfaction

75% were "satisfied" or "very satisfied" with LONHALA MAGNAIR

Overall Satisfaction

75% were "satisfied" or "very satisfied" with LONHALA MAGNAIR

 


As reported on a Sunovion-generate questionnaire (20 questions total). Results were similar throughout. Percentages rounded for simplicity.

FULL QUESTIONNAIRE RESPONSES 

References:
1. 
Kerwin EM, Donohue JF, Ferguson CT, Ganapathy V, Ozol-Godfrey A, Rajagopolan K. Satisfaction with the use of eFlow closed-system nebulizer in patients with moderate-to-very-severe chronic obstructive pulmonary disease: findings from a long-term safety study. J Aerosol Med Pulm Drug Deliv. 2019;32(1):24-33.
2. LONHALA MAGNAIR [manufacturer's instructions for use]. Marlborough, MA: Sunovion Pharmaceuticals Inc. 

Important Safety Information & Indication

Important Safety Information
 

LONHALA MAGNAIR is contraindicated in patients with a hypersensitivity to glycopyrrolate or to any of the ingredients.

LONHALA MAGNAIR should not be initiated in patients with acutely deteriorating or potentially life-threatening episodes of COPD or used as rescue therapy for acute episodes of bronchospasm. Acute symptoms should be treated with an inhaled short-acting beta2-agonist.

As with other inhaled medicines, LONHALA MAGNAIR can produce paradoxical bronchospasm that may be life-threatening. If paradoxical bronchospasm occurs following dosing with LONHALA MAGNAIR, it should be treated immediately with an inhaled, short-acting bronchodilator; LONHALA MAGNAIR should be discontinued immediately and alternative therapy instituted.

Immediate hypersensitivity reactions have been reported with LONHALA MAGNAIR. If signs occur, discontinue LONHALA MAGNAIR immediately and institute alternative therapy.

LONHALA MAGNAIR should be used with caution in patients with narrow-angle glaucoma and in patients with urinary retention. Prescribers and patients should be alert for signs and symptoms of acute narrow-angle glaucoma (e.g., eye pain or discomfort, blurred vision, visual halos or colored images in association with red eyes from conjunctival congestion and corneal edema) and of urinary retention (e.g., difficulty passing urine, painful urination), especially in patients with prostatic hyperplasia or bladder-neck obstruction. Patients should be instructed to consult a physician immediately should any of these signs or symptoms develop.

The most common adverse events reported in ≥2% of patients taking LONHALA MAGNAIR, and occurring more frequently than in patients taking placebo, were dyspnea (4.9% vs 3.0%) and urinary tract infection (2.1% vs 1.4%).

LONHALA solution is for oral inhalation only and should not be injected or swallowed. LONHALA vials should only be administered with MAGNAIR.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

For additional information, please see full Prescribing Information and Patient Information for LONHALA MAGNAIR at www.sunovionprofile.com/lonhala-magnair.

Indication
 

LONHALA® MAGNAIR® (glycopyrrolate) is an anticholinergic indicated for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.